Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose

Stefan Grudén, Anders Forslund, Göran Alderborn, Arvid Söderhäll, Per M. Hellström, Ulf Holmbäck

Open source

DOI
10.1002/cpdd.920
Published
2021-02-13
Container
Clinical Pharmacology in Drug Development
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cpdd.920,
  title = {Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose},
  author = {Stefan Grudén and Anders Forslund and Göran Alderborn and Arvid Söderhäll and Per M. Hellström and Ulf Holmbäck},
  year = {2021},
  journal = {Clinical Pharmacology in Drug Development},
  doi = {10.1002/cpdd.920},
  url = {https://doi.org/10.1002/cpdd.920}
}

RIS

TY  - JOUR
TI  - Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose
AU  - Stefan Grudén
AU  - Anders Forslund
AU  - Göran Alderborn
AU  - Arvid Söderhäll
AU  - Per M. Hellström
AU  - Ulf Holmbäck
PY  - 2021
JO  - Clinical Pharmacology in Drug Development
DO  - 10.1002/cpdd.920
UR  - https://doi.org/10.1002/cpdd.920
ER  - 

APA

Grudén, S., Forslund, A., Alderborn, G., Söderhäll, A., Hellström, P. M., & Holmbäck, U. (2021). Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.920

Source records